Stockreport

Immune-Onc Therapeutics Presents Updated Data from Phase 1b Study of IO-202 Highlighting Promising Efficacy and Safety Data in CMML Patients at 2024 American Society of Hematology (ASH) An...

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
PDF – CR rate of 83.3% and ORR of 100% in CMML patients with high LILRB4 expression – PALO ALTO, Calif., December 10, 2024 BUSINESS WIRE )--Immune-Onc Therapeutics, Inc. [Read more]